10:22 AM EDT, 04/21/2026 (MT Newswires) -- Moderna ( MRNA ) said Tuesday the European Commission has granted marketing authorization for its mCombriax vaccine for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.

The marketing authorization is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway, Moderna ( MRNA ) said.

The Commission's authorization is based on the results from the phase 3 clinical study evaluating the safety, reactogenicity, and immunogenicity of mCombriax in two independent age groups of about 4,000 adults each, Moderna ( MRNA ) said.

Price: 54.02, Change: -0.57, Percent Change: -1.04